keyword
MENU ▼
Read by QxMD icon Read
search

Ovarian clear cell carcinoma

keyword
https://www.readbyqxmd.com/read/29785550/does-tumor-grade-influence-the-rate-of-lymph-node-metastasis-in-apparent-early-stage-ovarian-cancer
#1
Dimitrios Nasioudis, Spyridon A Mastroyannis, Emily M Ko, Nawar A Latif
PURPOSE: To evaluate the prevalence of regional lymph node (LN) metastasis in patients with non-clear cell epithelial ovarian cancer apparently confined to the ovary, stratified by tumor grade. METHODS: The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database was accessed (1988-2014). We identified patients with epithelial ovarian carcinoma of serous, endometrioid and mucinous histology apparently confined to the ovary who underwent extensive lymphadenectomy (defined as at least 20 lymph nodes removed)...
May 21, 2018: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/29781825/prognostic-value-of-serum-ca19-9-and-perioperative-ca-125-levels-in-ovarian-clear-cell-carcinoma
#2
Jun Zhu, Long Jiang, Hao Wen, Rui Bi, Xiaohua Wu, Xingzhu Ju
BACKGROUND: There are no effective biomarkers for surveillance in ovarian clear cell carcinoma (OCCC), and the value of carbohydrate antigen 125 (CA-125) is limited. We sought to determine the value of both carbohydrate antigen 19-9 (CA19-9) and CA-125 levels postoperatively on the prognosis for OCCC. METHODS: A total of 130 patients with OCCC who were consecutively treated by cytoreduction at Fudan University Shanghai Cancer Center were reviewed retrospectively...
May 18, 2018: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29780776/preoperative-serum-levels-of-cancer-antigen-125-and-carcinoembryonic-antigen-ratio-can-improve-differentiation-between-mucinous-ovarian-carcinoma-and-other-epithelial-ovarian-carcinomas
#3
Ji Hui Choi, Geum Seon Sohn, Doo Byung Chay, Han Byoul Cho, Jae-Hoon Kim
Objective: The main aim of this study was to evaluate cancer antigen 125 (CA125)/carcinoembryonic antigen (CEA) ratio (CCR), as a reliable marker to differentiate ovarian mucinous carcinoma from other epithelial ovarian carcinomas (EOCs), namely serous, clear cell, and endometrioid carcinomas. Methods: Female patients suffering from different kinds of EOCs whom were subjected to elective surgery at the Gangnam Severance Hospital between January 2008 and December 2016, were included in this study...
May 2018: Obstetrics & Gynecology Science
https://www.readbyqxmd.com/read/29769513/ovarian-endometrioid-adenocarcinoma-arising-in-endometriosis-a-case-report
#4
K Nahar, B Ferdous, N Akhter, P A Shamsunnahar, K Khatun, S A Begum, M A Aziz
Malignant transformation of ovarian endometriosis was first described in 1925 by Sampson; later on it has been described in extragonadal regions by few authors also. Ovarian endometrioid and clear cell carcinoma are highly associated with endometriosis. Here we present a case of malignant transformation of ovarian endometrioma into endometrioid adenocarcinoma and review the clinical and pathological features of these tumors. A 45-years old infertile woman diagnosed as a case of bilateral chocolate cyst with pelvic endometriosis underwent total hysterectomy with bilateral salpingo-oophorectomy...
April 2018: Mymensingh Medical Journal: MMJ
https://www.readbyqxmd.com/read/29768245/exploring-the-potential-of-mucin-13-muc13-as-a-biomarker-for-carcinomas-and-other-diseases
#5
Panagiota S Filippou, Annie H Ren, Dimitrios Korbakis, Lampros Dimitrakopoulos, Antoninus Soosaipillai, Vivian Barak, Shahar Frenkel, Jacob Pe'er, Michal Lotem, Sharon Merims, Rafael Molina, Ivan Blasutig, Dimitrios P Bogdanos, Eleftherios P Diamandis
BACKGROUND: Mucin 13 (MUC13) is a cell surface glycoprotein aberrantly expressed in a variety of epithelial carcinomas. Thus far, the role of MUC13 in various diseases remains elusive. To the best of our knowledge, this is the first study to examine the potential of MUC13 as a serum biomarker in a variety of carcinomas and other conditions. METHODS: We developed a recombinant MUC13 protein, mouse monoclonal antibodies and enzyme immunoassay (ELISA) for MUC13. We used this assay to measure MUC13 levels in the supernatants of cancer cell lines and a large cohort of serum samples from healthy and diseased individuals...
May 16, 2018: Clinical Chemistry and Laboratory Medicine: CCLM
https://www.readbyqxmd.com/read/29760405/arid1a-mutation-sensitizes-most-ovarian-clear-cell-carcinomas-to-bet-inhibitors
#6
Katrien Berns, Joseph J Caumanns, E Marielle Hijmans, Annemiek M C Gennissen, Tesa M Severson, Bastiaan Evers, G Bea A Wisman, Gert Jan Meersma, Cor Lieftink, Roderick L Beijersbergen, Hiroaki Itamochi, Ate G J van der Zee, Steven de Jong, René Bernards
Current treatment for advanced stage ovarian clear cell cancer is severely hampered by a lack of effective systemic therapy options, leading to a poor outlook for these patients. Sequencing studies revealed that ARID1A is mutated in over 50% of ovarian clear cell carcinomas. To search for a rational approach to target ovarian clear cell cancers with ARID1A mutations, we performed kinome-centered lethality screens in a large panel of ovarian clear cell carcinoma cell lines. Using the largest OCCC cell line panel established to date, we show here that BRD2 inhibition is predominantly lethal in ARID1A mutated ovarian clear cell cancer cells...
May 15, 2018: Oncogene
https://www.readbyqxmd.com/read/29751993/adjuvant-chemotherapy-for-stage-i-ovarian-clear-cell-carcinoma-patterns-of-use-and-outcomes
#7
Dimitrios Nasioudis, Spyridon A Mastroyannis, Benjamin B Albright, Ashley F Haggerty, Emily M Ko, Nawar A Latif
OBJECTIVE: The aim of this study was to investigate the patterns of use and outcomes of adjuvant chemotherapy for patients diagnosed with FIGO stage I ovarian clear cell carcinoma (OCCC). METHODS: A cohort of patients diagnosed between 2004 and 2015 with OCCC was drawn from the National Cancer Database. Those with stage I disease who had primary surgery and underwent systematic lymphadenectomy (defined as at least 10 lymph nodes removed) were selected for further analysis...
May 8, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29750701/comprehensive-surgical-staging-in-stage-1-clear-cell-and-endometrioid-ovarian-carcinomas-is-it-necessary
#8
Radha R Padhy, Johanna Savage, Robert J Kurman
The objective of this article was to evaluate the presence of occult metastasis after comprehensive surgical staging of clear cell ovarian carcinoma (CCC) and endometrioid ovarian carcinoma (EMCA) that appeared to be confined to the ovary at time of surgery. Between 1998 to 2016, 85 patients with CCC and EMCA were identified who were comprehensively staged and felt to be stage 1 intraoperatively. Of the 85 patients who underwent surgical staging, 4 (4.7%) had omental and dense pelvic side-wall tumor adhesions...
May 10, 2018: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/29749539/somatic-copy-number-alterations-have-prognostic-impact-in-patients-with-ovarian-clear-cell-carcinoma
#9
Asuka Morikawa, Tomoatsu Hayashi, Mana Kobayashi, Yuki Kato, Katsuhiko Shirahige, Takehiko Itoh, Mitsuyoshi Urashima, Aikou Okamoto, Tetsu Akiyama
Ovarian clear cell carcinoma (OCCC) is a chemotherapy‑resistant epithelial ovarian cancer with poor prognosis. To identify genomic alterations involved in the development of OCCC, we analyzed somatic copy number alterations in OCCC using comparative genomic hybridization (CGH). Here we showed that the chromosomal regions 8p11.21, 8p11.22, 12p13.31 and 20q13.2 were amplified in OCCC. We also demonstrated that small segments in the chromosomal regions 3q26.1, 4q13.2 and 22q11.23 were deleted. Kaplan‑Meier survival analyses revealed that patients with amplification within 8p11...
May 8, 2018: Oncology Reports
https://www.readbyqxmd.com/read/29749467/kif20a-expression-as-a-prognostic-indicator-and-its-possible-involvement-in-the-proliferation-of-ovarian-clear%C3%A2-cell-carcinoma-cells
#10
Yosuke Kawai, Kiyosumi Shibata, Jun Sakata, Shiro Suzuki, Fumi Utsumi, Kaoru Niimi, Ryuichiro Sekiya, Takeshi Senga, Fumitaka Kikkawa, Hiroaki Kajiyama
Kinesin family member 20A (KIF20A), which is involved in cytokinesis and intracellular transportation, has been recently reported to be upregulated in several malignancies and may contribute to chemotherapeutic resistance. We examined the distribution and expression of KIF20A in clear‑cell carcinoma (CCC) of the ovary to elucidate its clinical significance and molecular mechanism. Paraffin sections from ovarian CCC tissues (N=43) were immunostained with KIF20A antibody, and the staining intensities were semi‑quantitatively evaluated...
April 25, 2018: Oncology Reports
https://www.readbyqxmd.com/read/29742675/risk-of-gynecologic-cancer-according-to-the-type-of-endometriosis
#11
Liisu Saavalainen, Heini Lassus, Anna But, Aila Tiitinen, Päivi Härkki, Mika Gissler, Eero Pukkala, Oskari Heikinheimo
OBJECTIVE: To assess the risks of gynecologic cancer according to the type of endometriosis in women with surgically verified endometriosis. METHODS: This is a population-based study of women with surgically verified endometriosis retrieved from the Finnish Hospital Discharge Register 1987-2012 (N=49,933); the subtypes of ovarian (n=23,210), peritoneal (n=20,187), and deep infiltrating (n=2,372) endometriosis were analyzed separately. Gynecologic cancers were obtained from the Finnish Cancer Registry...
May 7, 2018: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/29739622/phase-ii-study-of-single-agent-cabozantinib-in-patients-with-recurrent-clear-cell-ovarian-primary-peritoneal-or-fallopian-tube-cancer-nrg-gy001
#12
Panagiotis A Konstantinopoulos, William E Brady, John Farley, Amy Armstrong, Denise S Uyar, David M Gershenson
OBJECTIVE: To evaluate the efficacy and tolerability of cabozantinib in recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer. METHODS: Patients with recurrent ovarian, fallopian or primary peritoneal tumors with at least 50% clear cell histomorphology, measurable disease, one or two prior regimens and ECOG performance status 0-2 received cabozantinib 60 mg orally once daily continuously, in 4-week cycles until disease progression or unacceptable toxicity...
May 5, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29731792/immunohistochemical-characterization-of-normal-ovary-and-common-epithelial-ovarian-neoplasm-with-a-monoclonal-antibody-to-cytokeratin-and-vimentin
#13
Ankita Goel, Nandam Mohan Rao, Vissa Santhi, Syam Sundar Byna, Bhavana Grandhi, Jyothi Conjeevaram
Background & Objective: The common epithelial ovarian tumors are classified into serous, mucinous, clear cell, endometrioid, the Brenner, mixed, and undifferentiated types. Cytoskeleton intermediate filament composition of ovarian tissues indicates that the cytokeratin and vimentin are observed in ovarian surface epithelium along with the common ovarian epithelial tumors. The current study aimed at investigating the cytokeratin and vimentin expression in epithelial ovarian tumors to establish a diagnostic relevance...
2018: Iranian Journal of Pathology
https://www.readbyqxmd.com/read/29727055/prognostic-factors-for-maximally-or-optimally-cytoreduced-stage-iii-nonserous-epithelial-ovarian-carcinoma-treated-with-carboplatin-paclitaxel-chemotherapy
#14
Zeliha F Cuylan, Mehmet M Meydanli, Mustafa E Sari, Ozgur Akbayir, Husnu Celik, Murat Dede, Hanifi Sahin, Kemal Gungorduk, Esra Kuscu, Nejat Ozgul, Tayfun Gungor, Ali Ayhan
OBJECTIVE: To identify factors predictive of poor prognosis in women with stage III nonserous epithelial ovarian cancer (EOC) who had undergone maximal or optimal primary cytoreductive surgery (CRS) followed by six cycles of intravenous carboplatin/paclitaxel chemotherapy. METHODS: A multicenter, retrospective department database review was performed to identify patients with stage III nonserous EOC who had undergone maximal or optimal primary CRS followed by six cycles of carboplatin/paclitaxel chemotherapy at seven gynecological oncology centers in Turkey...
May 4, 2018: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/29725737/genomic-scar-signatures-associated-with-homologous-recombination-deficiency-predict-adverse-clinical-outcomes-in-patients-with-ovarian-clear-cell-carcinoma
#15
Angel Chao, Chyong-Huey Lai, Tzu-Hao Wang, Shih-Ming Jung, Yun-Shien Lee, Wei-Yang Chang, Lan-Yang Yang, Fei-Chun Ku, Huei-Jean Huang, An-Shine Chao, Chin-Jung Wang, Ting-Chang Chang, Ren-Chin Wu
We investigated whether genomic scar signatures associated with homologous recombination deficiency (HRD), which include telomeric allelic imbalance (TAI), large-scale transition (LST), and loss of heterozygosity (LOH), can predict clinical outcomes in patients with ovarian clear cell carcinoma (OCCC). We enrolled patients with OCCC (n = 80) and high-grade serous carcinoma (HGSC; n = 92) subjected to primary cytoreductive surgery, most of whom received platinum-based adjuvant chemotherapy. Genomic scar signatures based on genome-wide copy number data were determined in all participants and investigated in relation to prognosis...
May 3, 2018: Journal of Molecular Medicine: Official Organ of the "Gesellschaft Deutscher Naturforscher und Ärzte"
https://www.readbyqxmd.com/read/29725467/association-between-ovarian-cancer-and-advanced-endometriosis
#16
Michail Matalliotakis, Charoula Matalliotaki, George N Goulielmos, Evridiki Patelarou, Maria Tzardi, Demetrios A Spandidos, Aydin Arici, Ioannis Matalliotakis
We retrospectively analyzed clinicopathological data in two different countries over the past years on the association between ovarian endometriosis and ovarian carcinoma. Medical and pathological reports were evaluated from 1,000 patients with endometriosis from two different geographical areas. The prevalence and women characteristics of cases were analyzed. Endometriosis-associated ovarian cancer was present in 20 (2%) cases, among the study subjects. The observed prevalence was 12 (60%) for endometrioid carcinoma, 4 (20%) for clear cell ovarian carcinoma, 2 (10%) for serous and 2 (10%) for mucinous adenocarcinoma...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29721309/unraveling-endometriosis-associated-ovarian-carcinomas-using-integrative-proteomics
#17
Felix Leung, Marcus Q Bernardini, Kun Liang, Ihor Batruch, Marjan Rouzbahman, Eleftherios P Diamandis, Vathany Kulasingam
Background: To elucidate potential markers of endometriosis and endometriosis-associated endometrioid and clear cell ovarian carcinomas using mass spectrometry-based proteomics. Methods: A total of 21 fresh, frozen tissues from patients diagnosed with clear cell carcinoma, endometrioid carcinoma, endometriosis and benign endometrium were subjected to an in-depth liquid chromatography-tandem mass spectrometry analysis on the Q-Exactive Plus. Protein identification and quantification were performed using MaxQuant, while downstream analyses were performed using Perseus and various bioinformatics databases...
2018: F1000Research
https://www.readbyqxmd.com/read/29718305/invasive-epithelial-ovarian-cancer-survival-by-histotype-and-disease-stage
#18
Lauren C Peres, Kara L Cushing-Haugen, Martin Köbel, Holly R Harris, Andrew Berchuck, Mary Anne Rossing, Joellen M Schildkraut, Jennifer A Doherty
Background: The understanding of ovarian cancer pathogenesis has recently shifted to recognize distinct changes in how ovarian cancer histotypes are defined. Using the 2014 World Health Organization (WHO) diagnostic guidelines, we classified ovarian cancer histotypes in Surveillance, Epidemiology, and End Results (SEER) cancer registry data and examined survival patterns by histotype and disease stage. Methods: We extracted data on 28 118 incident epithelial ovarian cancer cases diagnosed in 2004-2014 from SEER and defined histotype using the 2014 WHO guidelines (high-grade serous, low-grade serous, endometrioid, clear cell, mucinous, carcinosarcoma, and malignant Brenner tumors)...
April 28, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29707125/the-hnf-1%C3%AE-usp28-claspin-pathway-upregulates-dna-damage-induced-chk1-activation-in-ovarian-clear-cell-carcinoma
#19
Fuminori Ito, Chiharu Yoshimoto, Yuki Yamada, Tamotsu Sudo, Hiroshi Kobayashi
Transcription factor hepatocyte nuclear factor 1-beta (HNF-1β) enhances checkpoint kinase 1 (Chk1) activation and promotes G2/M cell cycle progression in ovarian clear cell carcinoma (CCC) following exposure to diverse genotoxic agents including bleomycin. However, the underlying mechanism leading to checkpoint activation of HNF-1β still remains largely unknown. To clarify the effects of HNF-1β on cell cycle checkpoints, human CCC cell lines were transfected with siRNAs targeting HNF-1β, Claspin , USP28, or a control vector...
April 3, 2018: Oncotarget
https://www.readbyqxmd.com/read/29685880/integrative-kinome-profiling-identifies-mtorc1-2-inhibition-as-treatment-strategy-in-ovarian-clear-cell-carcinoma
#20
Joseph J Caumanns, Katrien Berns, G Bea A Wisman, Rudolf S N Fehrmann, Tushar Tomar, Harry Klip, Gert Jan Meersma, E Marielle Hijmans, Annemiek Gennissen, Evelien W Duiker, Desiree Weening, Hiroaki Itamochi, Roelof Jc Kluin, An K L Reyners, Michael J Birrer, Helga B Salvesen, Ignace Vergote, Els Van Nieuwenhuysen, James D Brenton, Elena I Braicu, Jolanta Kupryjanczyk, Beata Spiewankiewicz, Lorenza Mittempergher, Rene Bernards, Ate G J van der Zee, Steven de Jong
PURPOSE: Advanced stage ovarian clear cell carcinoma (OCCC) is unresponsive to conventional platinum-based chemotherapy. Frequent alterations in OCCC include deleterious mutations in the tumor suppressor ARID1A and activating mutations in the PI3K subunit PIK3CA. In this study, we aimed to identify currently unknown mutated kinases in OCCC patients and test druggability of downstream affected pathways in OCCC models. EXPERIMENTAL DESIGN: In a large set of OCCC patients (n=124), the human kinome (518 kinases) and additional cancer related genes were sequenced and copy number alterations were determined...
April 23, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
keyword
keyword
72420
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"